587 related articles for article (PubMed ID: 26102022)
21. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
Holmberg B; Rosengren L; Karlsson JE; Johnels B
Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
[TBL] [Abstract][Full Text] [Related]
22. Transcriptional changes in multiple system atrophy and Parkinson's disease putamen.
Vogt IR; Lees AJ; Evert BO; Klockgether T; Bonin M; Wüllner U
Exp Neurol; 2006 Jun; 199(2):465-78. PubMed ID: 16626704
[TBL] [Abstract][Full Text] [Related]
23. Subcortical
Cho H; Choi JY; Hwang MS; Lee SH; Ryu YH; Lee MS; Lyoo CH
Mov Disord; 2017 Jan; 32(1):134-140. PubMed ID: 27813160
[TBL] [Abstract][Full Text] [Related]
24. Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging.
Eckert T; Sailer M; Kaufmann J; Schrader C; Peschel T; Bodammer N; Heinze HJ; Schoenfeld MA
Neuroimage; 2004 Jan; 21(1):229-35. PubMed ID: 14741660
[TBL] [Abstract][Full Text] [Related]
25. The stimulator of interferon genes (STING) pathway is upregulated in striatal astrocytes of patients with multiple system atrophy.
Inoue Y; Ayaki T; Ishimoto T; Yamakado H; Maki T; Matsuzawa S; Sawamoto N; Takahashi R
Neurosci Lett; 2021 Jul; 757():135972. PubMed ID: 34033888
[TBL] [Abstract][Full Text] [Related]
26. Quantification of brain-derived extracellular vesicles in plasma as a biomarker to diagnose Parkinson's and related diseases.
Ohmichi T; Mitsuhashi M; Tatebe H; Kasai T; Ali El-Agnaf OM; Tokuda T
Parkinsonism Relat Disord; 2019 Apr; 61():82-87. PubMed ID: 30502924
[TBL] [Abstract][Full Text] [Related]
27. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET.
Juh R; Kim J; Moon D; Choe B; Suh T
Eur J Radiol; 2004 Sep; 51(3):223-33. PubMed ID: 15294329
[TBL] [Abstract][Full Text] [Related]
28. FBXO7 immunoreactivity in α-synuclein-containing inclusions in Parkinson disease and multiple system atrophy.
Zhao T; Severijnen LA; van der Weiden M; Zheng PP; Oostra BA; Hukema RK; Willemsen R; Kros JM; Bonifati V
J Neuropathol Exp Neurol; 2013 Jun; 72(6):482-8. PubMed ID: 23656991
[TBL] [Abstract][Full Text] [Related]
29. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
Im JH; Chung SJ; Kim JS; Lee MC
J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371
[TBL] [Abstract][Full Text] [Related]
30. Quantitative assessment of subcortical atrophy and iron content in progressive supranuclear palsy and parkinsonian variant of multiple system atrophy.
Lee JH; Han YH; Kang BM; Mun CW; Lee SJ; Baik SK
J Neurol; 2013 Aug; 260(8):2094-101. PubMed ID: 23670309
[TBL] [Abstract][Full Text] [Related]
31. Neuroinflammation and protein pathology in Parkinson's disease dementia.
Kouli A; Camacho M; Allinson K; Williams-Gray CH
Acta Neuropathol Commun; 2020 Dec; 8(1):211. PubMed ID: 33272323
[TBL] [Abstract][Full Text] [Related]
32. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
[TBL] [Abstract][Full Text] [Related]
33. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease.
Mirza B; Hadberg H; Thomsen P; Moos T
Neuroscience; 2000; 95(2):425-32. PubMed ID: 10658622
[TBL] [Abstract][Full Text] [Related]
34. MR findings in the substantia nigra on phase difference enhanced imaging in neurodegenerative parkinsonism.
Sugiyama A; Sato N; Kimura Y; Ota M; Maekawa T; Sone D; Enokizono M; Murata M; Matsuda H; Kuwabara S
Parkinsonism Relat Disord; 2018 Mar; 48():10-16. PubMed ID: 29279191
[TBL] [Abstract][Full Text] [Related]
35. Lysosomal response in relation to α-synuclein pathology differs between Parkinson's disease and multiple system atrophy.
Puska G; Lutz MI; Molnar K; Regelsberger G; Ricken G; Pirker W; Laszlo L; Kovacs GG
Neurobiol Dis; 2018 Jun; 114():140-152. PubMed ID: 29505813
[TBL] [Abstract][Full Text] [Related]
36. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
Sako W; Murakami N; Izumi Y; Kaji R
Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
[TBL] [Abstract][Full Text] [Related]
37. 5-methylcytosine and 5-hydroxymethylcytosine in brains of patients with multiple system atrophy and patients with Parkinson's disease.
Kaut O; Kuchelmeister K; Moehl C; Wüllner U
J Chem Neuroanat; 2019 Mar; 96():41-48. PubMed ID: 30557654
[TBL] [Abstract][Full Text] [Related]
38. Reduction of neuromelanin-positive nigral volume in patients with MSA, PSP and CBD.
Kashihara K; Shinya T; Higaki F
Intern Med; 2011; 50(16):1683-7. PubMed ID: 21841326
[TBL] [Abstract][Full Text] [Related]
39. The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease.
Bandopadhyay R; Kingsbury AE; Cookson MR; Reid AR; Evans IM; Hope AD; Pittman AM; Lashley T; Canet-Aviles R; Miller DW; McLendon C; Strand C; Leonard AJ; Abou-Sleiman PM; Healy DG; Ariga H; Wood NW; de Silva R; Revesz T; Hardy JA; Lees AJ
Brain; 2004 Feb; 127(Pt 2):420-30. PubMed ID: 14662519
[TBL] [Abstract][Full Text] [Related]
40. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
